A Phase 1 interventional study of Simvastatin and PF-05175157 in Type 2 Diabetes Mellitus, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-11-14.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing simvastatin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Simvastatin · Diabetes Mellitus, Type 2.
Among the 19 studies testing simvastatin in Diabetes Mellitus, Type 2, this one is the 19th largest by enrollment, is the only one that started in 2011, is one of 9 in phase 1, and was the 13th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 19 studies testing simvastatin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:
The University of Hong Kong · Sites in Hong Kong
Ages 50–74 · Women only
By country, each count listing its studies:
Simvastatin: first FDA approval 1991 (ZOCOR), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 1991; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 14 is below the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 33 across the 19 interventional studies. Of the 17 that completed or were terminated, 3 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 19 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
80 studies in Diabetes Mellitus, Type 2 by Pfizer: 2 open now, 3 under way, 3 of them phase 3. Of 77 finished, 39 (51%) have results posted.
Among the 80 studies in Diabetes Mellitus, Type 2 by Pfizer, this one is the 70th largest by enrollment of the 79 interventional ones that give a count, is one of 17 that started in 2011, is one of 47 in phase 1, and was the 45th registered.
Pfizer’s Diabetes Mellitus, Type 2 studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing simvastatin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 80 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The study is designed to investigate the effect of repeated dosing of PF-05175157 on the pharmacokinetics of a single dose of Simvastatin in healthy adult subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Simvastatin · Drug: PF-05175157
Day 1: Single dose of simvastatin 20 mg Day 8: single dose of simvastatin 20 mg (with PF-05175157)
Days 2-9 inclusive: daily dosing of PF-05175157 200 mg
Area under the plasma concentration curve of simvastatin and simvastatin acid
Time frame: 10 days
Maximum observed plasma concentration of simvastatin and simvastatin acid
Time frame: 10 days
Time at which maximum plasma concentration of simvastatin and simvastatin acid is observed
Time frame: 10 days
If the data permit, area under the plasma concentration curve of simvastatin and simvastatin acid extrapolated to infinite time
Time frame: 10 days
If the data permit, terminal elimination half-life of simvastatin and simvastatin acid
Time frame: 10 days
The record gives a start of Nov 2011, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Simvastatin · PF-05175157